Streetbeat News

Stock Prices

ZI

B of A Securities analyst Koji Ikeda has upgraded ZoomInfo Technologies (NASDAQ:ZI) from Neutral to Buy and increased the price target from $20 to $25.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 12:00 pm

DOGE-USD

Cryptocurrency analyst Muro predicts a 6% rise in Dogecoin's (CRYPTO: DOGE) value, with a target price of $0.083. Dogecoin recently saw a 10% increase after a new verified account related to a payment feature on an app associated with Elon Musk was set up. Muro's comments suggest a potential short-term price jump for DOGE, despite a recent pullback to its original trading price of $0.078.

Portfolio Pulse from Mehab Qureshi

January 29, 2024 | 11:59 am

DT

Needham analyst Mike Cikos reaffirmed a Buy rating on Dynatrace (NYSE:DT) and increased the price target from $60 to $70, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:57 am

BOOM

Trading for the stock with the symbol BOOM has been halted at 6:55 a.m. ET due to pending news. The halt is in place to manage market orderliness and investor protection pending the release of material news.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:55 am

AAL

Citigroup analyst Stephen Trent upgraded American Airlines Group (AAL) from Neutral to Buy and increased the price target from $14 to $20.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:54 am

RPD

UBS analyst Roger Boyd has upgraded Rapid7 (NASDAQ:RPD) from Neutral to Buy and increased the price target from $53 to $70, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:53 am

DLTR

Dollar Tree's stock (DLTR) is trading higher following an upgrade from JP Morgan, changing its rating from Neutral to Overweight. Additionally, JP Morgan increased the price target for Dollar Tree from $122 to $157.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:44 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a Buy rating on Genmab (NASDAQ:GMAB) and increased the price target from $49 to $50.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:40 am

BBIO

HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a Buy rating on BridgeBio Pharma (NASDAQ:BBIO) and increased the price target from $22 to $47, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:37 am

BIOL

Biolase projects its full-year 2024 revenue to be between $52M-$53M, reflecting a 6%-8% increase year-over-year, slightly below the consensus estimate of $53.01M. The company also anticipates improving its loss from operations by 50%-60%.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:37 am